Connor, Clark & Lunn Investment Management (CC&L)
KYMR icon

Connor, Clark & Lunn Investment Management (CC&L)’s Kymera Therapeutics KYMR Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.2M Buy
149,908
+45,629
+44% +$3.92M 0.03% 403
2026
Q1 		$8.69M Buy
+104,279
New +$8.26M 0.02% 515

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s KYMR Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Kymera Therapeutics (KYMR) stake by 44% in Q2 2026, buying an estimated $3.92M and bringing the position to 149,908 shares worth $17.2M. The position accounts for 0.03% of the portfolio, ranked #403.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in KYMR in Q1 2026 and has held it in 2 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 149,908 shares of Kymera Therapeutics worth $17.2M as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) bought 45,629 Kymera Therapeutics shares in Q2 2026, an estimated $3.92M.
  • Kymera Therapeutics made up 0.03% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #403 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Kymera Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.